157 related articles for article (PubMed ID: 36239936)
1. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.
Handley KF; Sims TT; Bateman NW; Glassman D; Foster KI; Lee S; Yao J; Yao H; Fellman BM; Liu J; Lu Z; Conrads KA; Hood BL; Barakat W; Zhao L; Zhang J; Westin SN; Celestino J; Rangel KM; Badal S; Pereira I; Ram PT; Maxwell GL; Eberlin LS; Futreal PA; Bast RC; Fleming ND; Conrads TP; Sood AK
JAMA Netw Open; 2022 Oct; 5(10):e2236626. PubMed ID: 36239936
[TBL] [Abstract][Full Text] [Related]
2. Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study.
Foster KI; Handley KF; Glassman D; Sims TT; Javadi S; Palmquist SM; Saleh MM; Fellman BM; Fleming ND; Bhosale PR; Sood AK
Int J Gynecol Cancer; 2023 Jun; 33(6):937-943. PubMed ID: 36948527
[TBL] [Abstract][Full Text] [Related]
3. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
4. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
5. Evolving population-based statistics for rare epithelial ovarian cancers.
Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
[TBL] [Abstract][Full Text] [Related]
6. Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study.
Hu D; Ma D; Zhang ZJ; Zhang Y; Huang K; Li X
Front Endocrinol (Lausanne); 2023; 14():1103429. PubMed ID: 36742399
[TBL] [Abstract][Full Text] [Related]
7. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
8. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.
Vargas HA; Miccò M; Hong SI; Goldman DA; Dao F; Weigelt B; Soslow RA; Hricak H; Levine DA; Sala E
Radiology; 2015 Mar; 274(3):742-51. PubMed ID: 25383459
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
10. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
11. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.
Lawrenson K; Fonseca MAS; Liu AY; Segato Dezem F; Lee JM; Lin X; Corona RI; Abbasi F; Vavra KC; Dinh HQ; Gill NK; Seo JH; Coetzee S; Lin YG; Pejovic T; Mhawech-Fauceglia P; Rowat AC; Drapkin R; Karlan BY; Hazelett DJ; Freedman ML; Gayther SA; Noushmehr H
Cell Rep; 2019 Dec; 29(11):3726-3735.e4. PubMed ID: 31825847
[TBL] [Abstract][Full Text] [Related]
12. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
Torres D; Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Wang C; Langstraat CL; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):223-227. PubMed ID: 30503050
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
[TBL] [Abstract][Full Text] [Related]
15. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
[TBL] [Abstract][Full Text] [Related]
16. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
17. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
18. Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
Torres D; Wang C; Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Konecny GE; Goode EL; Cliby WA
Gynecol Oncol; 2018 Aug; 150(2):227-232. PubMed ID: 29925470
[TBL] [Abstract][Full Text] [Related]
19. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
20. Clinico-pathologic characteristics and prognostic factors of ovarian carcinoma with different histologic subtypes - A benchmark analysis of 482 cases.
Brambs CE; Höhn AK; Klagges S; Gläser A; Taubenheim S; Dornhöfer N; Einenkel J; Hiller GGR; Horn LC
Pathol Res Pract; 2022 May; 233():153859. PubMed ID: 35378355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
